|
Q1 FY2027
As of Aug 31, 2026
|
Q4 FY2026
As of May 31, 2026
|
Q3 FY2026
As of Feb 28, 2026
|
Q2 FY2026
As of Nov 30, 2025
|
Q1 FY2026
As of Aug 31, 2025
|
Q4 FY2025
As of May 31, 2025
|
Q3 FY2025
As of Feb 28, 2025
|
Q2 FY2025
As of Nov 30, 2024
|
Q1 FY2025
As of Aug 31, 2024
|
Q4 FY2024
As of May 31, 2024
|
Q3 FY2024
As of Feb 29, 2024
|
Q2 FY2024
As of Nov 30, 2023
|
Q1 FY2024
As of Aug 31, 2023
|
Q4 FY2023
As of May 31, 2023
|
Q3 FY2023
As of Feb 28, 2023
|
Q2 FY2023
As of Nov 30, 2022
|
Q1 FY2023
As of Aug 31, 2022
|
Q1 FY2022
As of Aug 31, 2021
|
Q4 FY2021
As of May 31, 2021
|
Q3 FY2021
As of Feb 28, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Prepaid investment | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Music inventory | ||||||||||||||||||||
| Investment in Acquisition | ||||||||||||||||||||
| Loans receivable, related party | ||||||||||||||||||||
| Music inventory, net of accumulated depreciation of $-0- and $21,815, respectively | ||||||||||||||||||||
| Trademark costs | ||||||||||||||||||||
| Total Other Assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| Bank overdraft | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||||||
| Accrued interest payable on notes payable | ||||||||||||||||||||
| Accrued consulting fees, related parties | ||||||||||||||||||||
| Accrued consulting fees | ||||||||||||||||||||
| Notes payable, net of debt discounts of $11,808 and $31,709, respectively | ||||||||||||||||||||
| Notes payable | ||||||||||||||||||||
| Notes payable to related parties | ||||||||||||||||||||
| Derivative liability | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| Preferred Stock, $0.0001 par value; 20,000,000 shares authorized, 200 and 200 shares issued and outstanding | ||||||||||||||||||||
| Common stock, $0.0001 par value; 20,000,000,000 shares authorized, 536,029,662 and 24,981,619 shares issued and outstanding, respectively | ||||||||||||||||||||
| Common stock payable | ||||||||||||||||||||
| Additional paid-in-capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Stockholders’ Equity | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
Loading...
